Our previous research demonstrated that the small-molecule GRPR antagonist PD176252 alleviates CIS-induced nephrotoxicity, whereas RH-1402, a derivative designed based on PD176252, exhibits enhanced renal protective effects by reducing inflammation and mitigating kidney damage [21,27]. This evidence concerns the gene GRPR and in situ carcinoma.